{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-026864","form_type":"8-K","ticker":null,"cik":"0001783032","company_name":"Elevation Oncology, Inc.","filed_at":"2025-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.976126+00:00","generated_at":"2026-05-18T03:34:05.722736+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Elevation Oncology completes acquisition by Concentra Biosciences, shares delisted","bullets":["Concentra Biosciences acquires Elevation Oncology for $0.36 per share plus contingent value right (CVR).","67.09% of shares tendered in the offer, satisfying the Minimum Tender Condition.","All directors resign at closing; Kevin Tang becomes sole director of the surviving corporation.","CEO/CFO Tammy Furlong terminated without cause, receives 12 months salary plus $600,000 lump sum.","Company requests delisting from Nasdaq and deregistration under Exchange Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-026864","json":"https://secwatch.observer/filing/0001140361-25-026864.json","markdown":"https://secwatch.observer/filing/0001140361-25-026864.md","text":"https://secwatch.observer/filing/0001140361-25-026864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/0001140361-25-026864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/ef20052364_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-18T03:34:05.722736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cce34d5fb5316c8fb1ef64c6bf1a8fea64188f80","claim":"Elevation Oncology, Inc.: Amended and restated bylaws in their entirety.","evidence_excerpt":"the Company’s certificate of incorporation and bylaws were amended and restated in their entirety","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/0001140361-25-026864-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"d542ed1004b9ca77824f6d49db99f1b726f01559","claim":"Elevation Oncology, Inc.: Amended and restated certificate of incorporation in its entirety.","evidence_excerpt":"the Company’s certificate of incorporation and bylaws were amended and restated in their entirety","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/0001140361-25-026864-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"3cdf14a0f3bcfeb67e682a94eefc5069940c7d4b","claim":"Elevation Oncology, Inc. completed an acquisition involving Concentra Merger Sub VI, Inc. (a wholly owned subsidiary of Concentra Biosciences, LLC) for $0.36 per share plus one contingent value right (CVR) per share (closed 2025-07-23).","evidence_excerpt":"Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on July 23, 2025, Merger Sub completed a tender offer to purchase all of the Company’s outstanding shares of common stock, par value $0.0001 per share (the “ Common Stock ” and shares of Common Stock, “ Shares ”), in exchange for (i) $0.36 in cash per Share (the “Cash Amount”); plus (ii) one non-transferable contractual contingent value right per Share (each, a “CVR,” and each CVR together with the Cash Amount, the “ Offer Price ”), which CVR represents the right to receive potential payments pursuant to the terms and subject to the conditions of the contingent value rights agreement (the “ CVR Agreement ”), dated July 23, 2025, by and among Concentra, Merger Sub, Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, and Fortis Advisors LLC, a Delaware limited liability company, all subject to and in accordance with the terms and conditions set forth in the Offer","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/0001140361-25-026864-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Concentra Merger Sub VI, Inc. (a wholly owned subsidiary of Concentra Biosciences, LLC)"},{"label":"Consideration","value":"$0.36 per share plus one contingent value right (CVR) per share"},{"label":"Closing","value":"2025-07-23"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}